DUBLIN–(BUSINESS WIRE)–The “Depressive Disorders Market Industry Trends and Global Forecasts to 2035 – Distribution by Type of Depression, Type of Molecule, Type of Therapy, Route of Administration and Key Geographical Regions” report has been added to ResearchAndMarkets.com’s offering.
Depression is a mental health disorder characterized by a constant feeling of sadness and lack of interest in external stimuli. Notably, this chronic condition is considered among the leading causes of mental disability worldwide. In fact, it is worth mentioning that, globally, more than 300 million people of all age groups suffer from depression.
Moreover, depressive disorders are estimated to cause an economic burden of approximately USD 210 billion in the US, annually. Despite its widespread occurrence and substantial impact, less than 50% of people with this condition receive treatment in high-income countries, and this number drops to less than 10% in low-income countries. As a result, a large number of branded drugs and over 150 generic products have been approved by the FDA to treat depression among patients. Despite the availability of generics and other branded drugs, patients have voiced the need for better antidepressants.
Consequently, the rising demand for better antidepressants has led stakeholders to undertake various initiatives to develop interventions and drug / therapy candidates with novel mechanism of action to treat depression. Recently, stakeholders have begun relying more on personalized approaches, incorporating new therapies, such as Transcranial Direct Current Stimulation (tDCS) and ketamine, and exploring the link between the gut microbiome and depression.
Depressive Disorders Market: Research Coverage
- Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the depressive disorders market, focusing on key market segments, including type of depression, type of molecule, type of therapy, route of administration and key geographical regions.
- Market Landscape: A comprehensive evaluation of market landscape, based on several relevant parameters, such as information on drug developer(s), phase of development, type of molecule, type of therapy, type of depression, type of drug class, mechanism of action, dosing frequency and route of administration.
- Discontinued Drug Development Programs Case Study: In-depth assessment of discontinued drugs / trials, focusing on the number of discontinued drug development programs, year of discontinuation, geographical location, phase at which the development program was discontinued, mechanism of action of discontinued drug, disease indication, reason(s) for discontinuation and information on affiliated developer companies.
- Partnerships and Collaborations: A detailed analysis of the deals inked by stakeholders in this domain, based on various parameters, such as year of partnership, type of partnership, area of focus, type of depressive disorder, geography and most active players.
- Fundings and Investments: An in-depth analysis of the fundings received by players in depressive disorders domain, based on relevant parameters, such as number of funding instances, amount invested, type of funding, most active players, most active investors and geography.
- Clinical Trial Analysis: An insightful analysis of clinical trials related to depressive disorders, based on several parameters, such as trial registration year, current trial status, current trial phase, type of depressive disorder, mechanism of action, leading industry and non-industry players with highest number of completed / ongoing trials, regional distribution of clinical trials and enrolled patient population across different geographies.
- Clinical Trial Endpoints Analysis: A detailed analysis of the clinical endpoints in late-stage ongoing and planned studies, for various types of depressive disorders.
- Clinical and Commercial Attractiveness Analysis: A comprehensive assessment of clinical and commercial attractiveness of pipeline molecules based on several parameters, such as size of enrolled patient population, route of administration, therapy type and dosing frequency, target patient population, expected launch date and size of developer company.
- Key Commercialization Strategies: A detailed discussion on the various strategies that can be adopted by the drug developers across key commercialization stages including a timeline representation of the key strategies adopted.
- Digital Therapeutics for Depressive Disorders Case Study: A detailed discussion on the upcoming digital health solutions for the management / treatment of depression, featuring information on the various product development pathways adopted by companies involved in this segment of the market.
Depressive Disorders Market: Key Insights
- Over the past few years, the depressive disorders market has witnessed multiple clinical stage drug failures; amongst the various reported reasons, inability to achieve specific clinical endpoints was the most common.
- The current market landscape is fragmented, featuring small companies and established pharma giants, which are engaged in the development of over 65 drug candidates for treating different forms of depression.
- Several molecules in the development pipeline are in the late stages of clinical development; majority of the drugs are monotherapies and designed for delivery via oral route.
- With several marketed drugs and a healthy clinical pipeline, the opportunity in this domain is expected to evolve steadily as more product candidates get approved.
- Majority of the lead molecules are being evaluated as monotherapies; however, developers are also evaluating certain drugs as an adjunctive or combination therapy.
- Currently, the depressive drugs pipeline is dominated by orally administrable drugs; however, other routes of administration, such as nasal and transdermal, are also being investigated.
- Although clinical studies are registered across various geographies, maximum number of trials are being conducted in North America; over 70% of clinical trials are evaluating drugs in Phase II / Phase III.
- In lieu of the evolving product landscape, drug developers are putting in significant efforts to ensure that their candidates are clinically and commercially competent.
- A substantial proportion of partnerships in this domain are focused on digital therapeutics initiatives; with over USD 3 billion investments since 2010, companies have received active support from investors.
- Companies, such as Janssen Pharmaceutical, Lundbeck, Vistagen Therapeutics, Takeda Pharmaceutical and Otsuka Pharmaceutical, have signed multiple deals related to depressive disorders; majority of the aforementioned agreements were signed for R&D purpose.
- Around 60% of the total amount was invested in the last three years. Specifically, companies engaged in this domain had collectively raised USD 650 million. Overall, a sum of USD 2.8 billion was raised by various industry stakeholders through secondary offerings.
- Stakeholders are exploring diverse commercialization strategies across different stages of a product’s launch cycle; with drugs nearing patent expiry, developers are expected to adopt lifecycle management approaches.
Reasons to Buy this Report
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
Additional Benefits
- Complimentary PPT Insights Packs
- Complimentary Excel Data Packs for all Analytical Modules in the Report
- 15% Free Content Customization
- Detailed Report Walkthrough Session with Research Team
- Free Updated report if the report is 6-12 months old or older
Clinical and Commercial Attractiveness Analysis
- Chapter Overview
- Methodology
- Assumptions and Key Parameters
- Clinical and Commercial Attractiveness Analysis: Depressive Disorders
- Clinical and Commercial Attractiveness Analysis: Major Depressive Disorder
- Clinical and Commercial Attractiveness Analysis: Bipolar Disorder
- Clinical and Commercial Attractiveness Analysis: Other Types of Depressive Disorder
Key Commercialization Strategies
- Chapter Overview
- Successful Drug Launch Strategy: ROOTS Framework
- Successful Drug Launch Strategy: Product Differentiation
- Commercialization Strategies Adopted Based on Development Stage of Product
- Approved Molecules for Treating Depressive Disorders
- Abilify Mycite
- Abilify Maintena
- Rexulti
- Vraylar
- Trintellix
- Fetzima
- Latuda
- Viibryd
- Key Commercialization Strategies Adopted by the Companies Focused on Depressive Disorders
- Strategies Adopted Before the Approval of Drug
- Participation in Global Events
- Strategies Adopted During the Launch of Drug
- Collaboration with Internal Stakeholders and Pharmaceutical Firms
- Awareness through Product Websites
- Direct to Consumer (DTC) Advertisements
- Strategies Adopted Post Drug Launch / Near Patent Expiry of Drug
- Approval of Drug in Multiple Geographies
- Approval of Drug for Multiple Indications
- Concluding Remarks
Digital Therapeutics For Depressive Disorders
- Chapter Overview
- An Overview on Digital Therapeutics
- Development and Commercialization Pathway for Digital Therapeutics
- Discovery and Preclinical Research
- Clinical Trials and Validation
- Engaging Insurance Providers / Payers
- Distribution and Marketing
- Digital Therapeutics for Depressive Disorders
- Standalone Software Applications
- Personal Coaching
- AI Support
- Gaming Solutions
- Concluding Remarks
Companies Featured
- AbbVie
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly
- GSK
- Lundbeck
- Johnson & Johnson
- Merck
- Pfizer
- Sanofi
For more information about this report visit https://www.researchandmarkets.com/r/4upf7r
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900